Drug Profile
AZX 1101
Alternative Names: AZX1101Latest Information Update: 22 Sep 2021
Price :
$50
*
At a glance
- Originator AzurRx BioPharma
- Class Antibacterials; Enzymes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nosocomial infections
Most Recent Events
- 13 Sep 2021 AzurRx BioPharma has acquired First Wave Bio and then later changed its name to First Wave BioPharma
- 28 Jan 2021 No recent reports of development identified for preclinical development in Nosocomial-infections(Prevention) in France (PO)
- 08 May 2018 AzurRx BioPharma plans to file an IND application with the US FDA for Nosocomial infections by the end of 2018